+关注
不平凡的世界
暂无个人介绍
IP属地：广东
26
关注
0
粉丝
0
主题
0
勋章
主贴
热门
不平凡的世界
2021-07-12
冫
@老虎APP功能介绍:【成交占比】帮助说明
不平凡的世界
2023-04-17
这篇文章不错，转发给大家看看
Calithera Biosciences Inc盘中异动 快速下跌79.28%
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3463099494384997","uuid":"3463099494384997","gmtCreate":1500016579817,"gmtModify":1500017377294,"name":"不平凡的世界","pinyin":"bpfdsjbupingfandeshijie","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":26,"tweetSize":2,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.07","exceedPercentage":"80.57%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":651801116,"gmtCreate":1681726192935,"gmtModify":1681727089400,"author":{"id":"3463099494384997","authorId":"3463099494384997","name":"不平凡的世界","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3463099494384997","authorIdStr":"3463099494384997"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/651801116","repostId":"2302777316","repostType":2,"repost":{"id":"2302777316","kind":"news","pubTimestamp":1673274678,"share":"https://www.laohu8.com/m/news/2302777316?lang=&edition=full","pubTime":"2023-01-09 22:31","market":"us","language":"zh","title":"Calithera Biosciences Inc盘中异动 快速下跌79.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2302777316","media":"自选股智能写手","summary":"北京时间2023年01月09日22时31分，Calithera Biosciences Inc股票出现波动，股价快速跳水79.28%。Calithera Biosciences Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Apexigen Inc C/Wts 29/07/2027 、Cincor Pharma Inc、Albireo Pharma Inc涨幅较大，Sonnet Biotherapeutics Hldgs Inc、Context Therapeutics Inc、Apexigen Inc较为活跃，换手率分别为87.15%、84.14%、35.79%，振幅较大的相关个股有Apexigen Inc C/Wts 29/07/2027 、Marizyme Incorporated、Longboard Pharmaceuticals Inc，振幅分别为158.69%、35.33%、19.25%。Calithera Biosciences Inc公司简介：Calithera Biosciences Inc是一家临床阶段的制药公司。消息层面，截至22时31分，Calithera Biosciences Inc股票正面舆情新闻比例100%。","content":"<html><body><article><p>北京时间2023年01月09日22时31分，<a href=\"https://laohu8.com/S/CALA\">Calithera Biosciences</a> Inc（CALA.us）股票出现波动，股价快速跳水79.28%。截至发稿，该股报0.750美元/股，成交量138.425万股，<span>换手率</span>28.45%，振幅0.28%。</p><p>最近的财报数据显示，该股实现<span>营业收入</span>0.00美元，<span>净利润</span>-9.80百万美元，<span>每股收益</span>-2.01美元，<span>毛利</span>-348000.00美元，市盈率-0.03倍。</p><p>机构评级方面，在所有3家参与评级的机构中，33%的券商给予买入建议，67%的券商给予持有建议，无券商给予卖出建议。</p><p>Calithera Biosciences Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Cincor Pharma Inc、Albireo Pharma Inc涨幅较大，Sonnet Biotherapeutics Hldgs Inc、Context Therapeutics Inc、Apexigen Inc较为活跃，换手率分别为87.15%、84.14%、35.79%，振幅较大的相关个股有Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Marizyme Incorporated、Longboard Pharmaceuticals Inc，振幅分别为158.69%、35.33%、19.25%。</p><p>Calithera Biosciences Inc公司简介：Calithera Biosciences Inc是一家临床阶段的制药公司。该公司的业务活动贯穿美国地区。研究重点是发现和开发针对肿瘤和控制肿瘤微环境中关键代谢途径的免疫细胞靶标的小分子药物。其主要候选产品是CB-839，一种治疗实体肿瘤的谷氨酰胺酶抑制剂。它的另一个候选产品CB-1158正在开发中，用于血液学和肿瘤学适应症。</p><p>消息层面，截至22时31分，Calithera Biosciences Inc股票正面舆情新闻比例100%。</p><p>（以上内容为自选股<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Calithera Biosciences Inc盘中异动 快速下跌79.28%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalithera Biosciences Inc盘中异动 快速下跌79.28%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-09 22:31 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109223118824d1931&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2023年01月09日22时31分，Calithera Biosciences Inc（CALA.us）股票出现波动，股价快速跳水79.28%。截至发稿，该股报0.750美元/股，成交量138.425万股，换手率28.45%，振幅0.28%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-9.80百万美元，每股收益-2.01美元，毛利-348000.00美元，市盈率-0.03倍。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109223118824d1931&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CALA":"Calithera Biosciences, Inc.","BK4139":"生物科技"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109223118824d1931&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2302777316","content_text":"北京时间2023年01月09日22时31分，Calithera Biosciences Inc（CALA.us）股票出现波动，股价快速跳水79.28%。截至发稿，该股报0.750美元/股，成交量138.425万股，换手率28.45%，振幅0.28%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-9.80百万美元，每股收益-2.01美元，毛利-348000.00美元，市盈率-0.03倍。机构评级方面，在所有3家参与评级的机构中，33%的券商给予买入建议，67%的券商给予持有建议，无券商给予卖出建议。Calithera Biosciences Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Cincor Pharma Inc、Albireo Pharma Inc涨幅较大，Sonnet Biotherapeutics Hldgs Inc、Context Therapeutics Inc、Apexigen Inc较为活跃，换手率分别为87.15%、84.14%、35.79%，振幅较大的相关个股有Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Marizyme Incorporated、Longboard Pharmaceuticals Inc，振幅分别为158.69%、35.33%、19.25%。Calithera Biosciences Inc公司简介：Calithera Biosciences Inc是一家临床阶段的制药公司。该公司的业务活动贯穿美国地区。研究重点是发现和开发针对肿瘤和控制肿瘤微环境中关键代谢途径的免疫细胞靶标的小分子药物。其主要候选产品是CB-839，一种治疗实体肿瘤的谷氨酰胺酶抑制剂。它的另一个候选产品CB-1158正在开发中，用于血液学和肿瘤学适应症。消息层面，截至22时31分，Calithera Biosciences Inc股票正面舆情新闻比例100%。（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）","news_type":1},"isVote":1,"tweetType":1,"viewCount":809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":146461369,"gmtCreate":1626097030751,"gmtModify":1626097030751,"author":{"id":"3463099494384997","authorId":"3463099494384997","name":"不平凡的世界","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3463099494384997","authorIdStr":"3463099494384997"},"themes":[],"htmlText":"冫 ","listText":"冫 ","text":"冫","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146461369","repostId":"394997061","repostType":1,"repost":{"id":394997061,"gmtCreate":1607917656653,"gmtModify":1703850043002,"author":{"id":"3562804614994746","authorId":"3562804614994746","name":"老虎APP功能介绍","avatar":"https://static.tigerbbs.com/5a8e4414a77df621346870c2f7e7cab7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562804614994746","authorIdStr":"3562804614994746"},"themes":[],"title":"【成交占比】帮助说明","htmlText":"一、什么是成交占比成交占比展示两个数据：每个交易日该股票的未平仓合约数和成交量占未平仓合约数的比值。换言之，本模块直观展示期权被换手的程度。二、如何使用场景1：成交量占比和未平仓数都上涨，说明什么？这意味着看涨或看跌的某一方在大量买进，正股未来可能产生单边走势，并反过来进一步影响期权价格。场景2: 只有成交量占比上涨，未平仓数稳定甚至下跌，这预期单边行情吗？并不，这说明期权换手率高，是股票正在进行多空争夺的表现。这种情况下，需要投资者结合其他信号、资讯等来进行综合分析。三、功能入口个股页-期权Tab-期权分析","listText":"一、什么是成交占比成交占比展示两个数据：每个交易日该股票的未平仓合约数和成交量占未平仓合约数的比值。换言之，本模块直观展示期权被换手的程度。二、如何使用场景1：成交量占比和未平仓数都上涨，说明什么？这意味着看涨或看跌的某一方在大量买进，正股未来可能产生单边走势，并反过来进一步影响期权价格。场景2: 只有成交量占比上涨，未平仓数稳定甚至下跌，这预期单边行情吗？并不，这说明期权换手率高，是股票正在进行多空争夺的表现。这种情况下，需要投资者结合其他信号、资讯等来进行综合分析。三、功能入口个股页-期权Tab-期权分析","text":"一、什么是成交占比成交占比展示两个数据：每个交易日该股票的未平仓合约数和成交量占未平仓合约数的比值。换言之，本模块直观展示期权被换手的程度。二、如何使用场景1：成交量占比和未平仓数都上涨，说明什么？这意味着看涨或看跌的某一方在大量买进，正股未来可能产生单边走势，并反过来进一步影响期权价格。场景2: 只有成交量占比上涨，未平仓数稳定甚至下跌，这预期单边行情吗？并不，这说明期权换手率高，是股票正在进行多空争夺的表现。这种情况下，需要投资者结合其他信号、资讯等来进行综合分析。三、功能入口个股页-期权Tab-期权分析","images":[{"img":"https://static.tigerbbs.com/489801d5e346843cf442c6a4c1d53cc2"},{"img":"https://static.tigerbbs.com/abff96600b466a7f9595deda509866b7"},{"img":"https://static.tigerbbs.com/aa1c99a4d688eb5e25756d2f2a9143f8"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/394997061","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1000,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":146461369,"gmtCreate":1626097030751,"gmtModify":1626097030751,"author":{"id":"3463099494384997","authorId":"3463099494384997","name":"不平凡的世界","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3463099494384997","authorIdStr":"3463099494384997"},"themes":[],"htmlText":"冫 ","listText":"冫 ","text":"冫","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/146461369","repostId":"394997061","repostType":1,"repost":{"id":394997061,"gmtCreate":1607917656653,"gmtModify":1703850043002,"author":{"id":"3562804614994746","authorId":"3562804614994746","name":"老虎APP功能介绍","avatar":"https://static.tigerbbs.com/5a8e4414a77df621346870c2f7e7cab7","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3562804614994746","authorIdStr":"3562804614994746"},"themes":[],"title":"【成交占比】帮助说明","htmlText":"一、什么是成交占比成交占比展示两个数据：每个交易日该股票的未平仓合约数和成交量占未平仓合约数的比值。换言之，本模块直观展示期权被换手的程度。二、如何使用场景1：成交量占比和未平仓数都上涨，说明什么？这意味着看涨或看跌的某一方在大量买进，正股未来可能产生单边走势，并反过来进一步影响期权价格。场景2: 只有成交量占比上涨，未平仓数稳定甚至下跌，这预期单边行情吗？并不，这说明期权换手率高，是股票正在进行多空争夺的表现。这种情况下，需要投资者结合其他信号、资讯等来进行综合分析。三、功能入口个股页-期权Tab-期权分析","listText":"一、什么是成交占比成交占比展示两个数据：每个交易日该股票的未平仓合约数和成交量占未平仓合约数的比值。换言之，本模块直观展示期权被换手的程度。二、如何使用场景1：成交量占比和未平仓数都上涨，说明什么？这意味着看涨或看跌的某一方在大量买进，正股未来可能产生单边走势，并反过来进一步影响期权价格。场景2: 只有成交量占比上涨，未平仓数稳定甚至下跌，这预期单边行情吗？并不，这说明期权换手率高，是股票正在进行多空争夺的表现。这种情况下，需要投资者结合其他信号、资讯等来进行综合分析。三、功能入口个股页-期权Tab-期权分析","text":"一、什么是成交占比成交占比展示两个数据：每个交易日该股票的未平仓合约数和成交量占未平仓合约数的比值。换言之，本模块直观展示期权被换手的程度。二、如何使用场景1：成交量占比和未平仓数都上涨，说明什么？这意味着看涨或看跌的某一方在大量买进，正股未来可能产生单边走势，并反过来进一步影响期权价格。场景2: 只有成交量占比上涨，未平仓数稳定甚至下跌，这预期单边行情吗？并不，这说明期权换手率高，是股票正在进行多空争夺的表现。这种情况下，需要投资者结合其他信号、资讯等来进行综合分析。三、功能入口个股页-期权Tab-期权分析","images":[{"img":"https://static.tigerbbs.com/489801d5e346843cf442c6a4c1d53cc2"},{"img":"https://static.tigerbbs.com/abff96600b466a7f9595deda509866b7"},{"img":"https://static.tigerbbs.com/aa1c99a4d688eb5e25756d2f2a9143f8"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/394997061","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":1000,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":651801116,"gmtCreate":1681726192935,"gmtModify":1681727089400,"author":{"id":"3463099494384997","authorId":"3463099494384997","name":"不平凡的世界","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3463099494384997","authorIdStr":"3463099494384997"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/651801116","repostId":"2302777316","repostType":2,"repost":{"id":"2302777316","kind":"news","pubTimestamp":1673274678,"share":"https://www.laohu8.com/m/news/2302777316?lang=&edition=full","pubTime":"2023-01-09 22:31","market":"us","language":"zh","title":"Calithera Biosciences Inc盘中异动 快速下跌79.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2302777316","media":"自选股智能写手","summary":"北京时间2023年01月09日22时31分，Calithera Biosciences Inc股票出现波动，股价快速跳水79.28%。Calithera Biosciences Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Apexigen Inc C/Wts 29/07/2027 、Cincor Pharma Inc、Albireo Pharma Inc涨幅较大，Sonnet Biotherapeutics Hldgs Inc、Context Therapeutics Inc、Apexigen Inc较为活跃，换手率分别为87.15%、84.14%、35.79%，振幅较大的相关个股有Apexigen Inc C/Wts 29/07/2027 、Marizyme Incorporated、Longboard Pharmaceuticals Inc，振幅分别为158.69%、35.33%、19.25%。Calithera Biosciences Inc公司简介：Calithera Biosciences Inc是一家临床阶段的制药公司。消息层面，截至22时31分，Calithera Biosciences Inc股票正面舆情新闻比例100%。","content":"<html><body><article><p>北京时间2023年01月09日22时31分，<a href=\"https://laohu8.com/S/CALA\">Calithera Biosciences</a> Inc（CALA.us）股票出现波动，股价快速跳水79.28%。截至发稿，该股报0.750美元/股，成交量138.425万股，<span>换手率</span>28.45%，振幅0.28%。</p><p>最近的财报数据显示，该股实现<span>营业收入</span>0.00美元，<span>净利润</span>-9.80百万美元，<span>每股收益</span>-2.01美元，<span>毛利</span>-348000.00美元，市盈率-0.03倍。</p><p>机构评级方面，在所有3家参与评级的机构中，33%的券商给予买入建议，67%的券商给予持有建议，无券商给予卖出建议。</p><p>Calithera Biosciences Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Cincor Pharma Inc、Albireo Pharma Inc涨幅较大，Sonnet Biotherapeutics Hldgs Inc、Context Therapeutics Inc、Apexigen Inc较为活跃，换手率分别为87.15%、84.14%、35.79%，振幅较大的相关个股有Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Marizyme Incorporated、Longboard Pharmaceuticals Inc，振幅分别为158.69%、35.33%、19.25%。</p><p>Calithera Biosciences Inc公司简介：Calithera Biosciences Inc是一家临床阶段的制药公司。该公司的业务活动贯穿美国地区。研究重点是发现和开发针对肿瘤和控制肿瘤微环境中关键代谢途径的免疫细胞靶标的小分子药物。其主要候选产品是CB-839，一种治疗实体肿瘤的谷氨酰胺酶抑制剂。它的另一个候选产品CB-1158正在开发中，用于血液学和肿瘤学适应症。</p><p>消息层面，截至22时31分，Calithera Biosciences Inc股票正面舆情新闻比例100%。</p><p>（以上内容为自选股<a href=\"https://laohu8.com/S/5RE.SI\">智能</a>机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Calithera Biosciences Inc盘中异动 快速下跌79.28%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalithera Biosciences Inc盘中异动 快速下跌79.28%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-09 22:31 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109223118824d1931&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2023年01月09日22时31分，Calithera Biosciences Inc（CALA.us）股票出现波动，股价快速跳水79.28%。截至发稿，该股报0.750美元/股，成交量138.425万股，换手率28.45%，振幅0.28%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-9.80百万美元，每股收益-2.01美元，毛利-348000.00美元，市盈率-0.03倍。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109223118824d1931&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CALA":"Calithera Biosciences, Inc.","BK4139":"生物科技"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109223118824d1931&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2302777316","content_text":"北京时间2023年01月09日22时31分，Calithera Biosciences Inc（CALA.us）股票出现波动，股价快速跳水79.28%。截至发稿，该股报0.750美元/股，成交量138.425万股，换手率28.45%，振幅0.28%。最近的财报数据显示，该股实现营业收入0.00美元，净利润-9.80百万美元，每股收益-2.01美元，毛利-348000.00美元，市盈率-0.03倍。机构评级方面，在所有3家参与评级的机构中，33%的券商给予买入建议，67%的券商给予持有建议，无券商给予卖出建议。Calithera Biosciences Inc股票所在的生物技术行业中，整体跌幅为1.72%。其相关个股中，Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Cincor Pharma Inc、Albireo Pharma Inc涨幅较大，Sonnet Biotherapeutics Hldgs Inc、Context Therapeutics Inc、Apexigen Inc较为活跃，换手率分别为87.15%、84.14%、35.79%，振幅较大的相关个股有Apexigen Inc C/Wts 29/07/2027 (To Pur Com)、Marizyme Incorporated、Longboard Pharmaceuticals Inc，振幅分别为158.69%、35.33%、19.25%。Calithera Biosciences Inc公司简介：Calithera Biosciences Inc是一家临床阶段的制药公司。该公司的业务活动贯穿美国地区。研究重点是发现和开发针对肿瘤和控制肿瘤微环境中关键代谢途径的免疫细胞靶标的小分子药物。其主要候选产品是CB-839，一种治疗实体肿瘤的谷氨酰胺酶抑制剂。它的另一个候选产品CB-1158正在开发中，用于血液学和肿瘤学适应症。消息层面，截至22时31分，Calithera Biosciences Inc股票正面舆情新闻比例100%。（以上内容为自选股智能机器写手Money Call完成，仅作为用户看盘参考，不作为交易依据。）","news_type":1},"isVote":1,"tweetType":1,"viewCount":809,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
